Search | Clinical Trials Finder

Conditions: Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult
Interventions: Epcoritamab, Rituximab; Drug
Lead sponsor: Reid Merryman, MD; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Rochester, New York + 2 more

Conditions: Central Precocious Puberty (CPP)
Interventions: Leuprolide Acetate (LA); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 17
States / cities: Long Beach, California • San Diego, California • Aurora, Colorado + 14 more

Conditions: Healthy Volunteers
Interventions: Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 394 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 8
States / cities: Anaheim, California • Cypress, California • Miami, Florida + 5 more

Conditions: Parkinson's Disease (PD)
Interventions: Optimized antiparkinsonian treatment, Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy ambulatory infusion pump, Percutaneous endoscopic gastrostomy tube, Jejunal extension tube; Drug · Device
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Port Charlotte, Florida • Round Rock, Texas

Conditions: Chronic Pancreatitis
Interventions: CREON; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Stanford, California • Gainesville, Florida • Baltimore, Maryland + 3 more

Conditions: Acute Myeloid Leukemia
Interventions: Pivekimab Sunirine, Venetoclax, Azacitidine, Matching Placebo for PVEK; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 6
States / cities: Duarte, California • Tampa, Florida • Atlanta, Georgia + 3 more

Conditions: Early Rheumatoid Arthritis
Interventions: adalimumab, methotrexate; Biological · Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 30
States / cities: Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 26 more

Conditions: Alopecia Areata
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 63 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 78
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more

Conditions: Metastatic Breast Cancer
Interventions: Veliparib Placebo, Veliparib, Carboplatin, Paclitaxel; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 56
States / cities: Gilbert, Arizona • Little Rock, Arkansas • Duarte, California + 48 more

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: Elsubrutinib, Placebo for Elsubrutinib, Upadacitinib, Placebo for Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 21
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Alamitos, California + 18 more

Conditions: Endometriosis, Chronic Pelvic Pain, Dysmenorrhea
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 117
States / cities: Birmingham, Alabama • Decatur, Alabama • Fairhope, Alabama + 93 more

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: ABT-089, Placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 60 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 12
States / cities: Lafayette, California • Jacksonville, Florida • Orlando, Florida + 9 more

Conditions: Myelodysplastic Syndromes (MDS)
Interventions: venetoclax, azacitidine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 10
States / cities: Tucson, Arizona • Aurora, Colorado • New Haven, Connecticut + 6 more

Conditions: Acute Myeloid Leukemia
Interventions: Fludarabine, Cytarabine, Gemtuzumab Ozogamicin, Azacitidine, Venetoclax; Drug
Lead sponsor: PedAL BCU, LLC; Other
Eligibility: 29 Days to 21 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 45
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 40 more

Conditions: Pain
Interventions: Hydrocodone/Acetaminophen Extended Release, Placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 3
States / cities: Pasadena, California • Austin, Texas • Salt Lake City, Utah

Conditions: Non Small Cell Lung Cancer, Cancer
Interventions: Venetoclax, Pembrolizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 39
States / cities: Birmingham, Alabama • Tucson, Arizona • Santa Rosa, California + 31 more

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 99 Years
Enrollment: 1,310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 47
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Long Beach, California + 41 more

Conditions: Hypogonadism, Cardiovascular Diseases
Interventions: AndroGel®, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 5,246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 379
States / cities: Alabaster, Alabama • Birmingham, Alabama • Decatur, Alabama + 262 more

Conditions: Schizophrenia
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 42
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 35 more

Conditions: Lung Cancer, NSCLC, Non-Small-Cell Lung Cancer
Interventions: ABT-751, pemetrexed, placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 27
States / cities: Fayetteville, Arkansas • Hot Springs, Arkansas • Greenbrae, California + 23 more

Conditions: Parkinson's Disease
Interventions: ABBV-951; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more

Conditions: Major Depressive Disorder
Interventions: Cariprazine, Placebo, Antidepressant Therapy (ADT); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 58
States / cities: Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more

Conditions: Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer
Interventions: ABBV-400, Trifluridine/Tipiracil, Bevacizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 18
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 13 more

Conditions: Non Small Cell Lung Carcinoma, c-MET
Interventions: Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 27
States / cities: Phoenix, Arizona • Fullerton, California • Oxnard, California + 24 more

Search by objective public record fields.

Epcoritamab and Rituximab for First-line Follicular Lymphoma

A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants

A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)

Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

A Study of Women Receiving Standard of Care (SOC) for the Treatment of Pelvic Pain Due to Suspected or Confirmed Endometriosis and the Impact on the Disease or Symptom Progression.

Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Acute Pain Study Following Bunionectomy

A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia

A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer

Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease

The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations